Literature DB >> 20197392

ABL alternative splicing is quite frequent in normal population - letter.

Iñigo Santamaria, Ana S Pitiot, Milagros Balbin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20197392     DOI： 10.1158/1535-7163.MCT-09-0078

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  4 in total

1.  Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.

Authors:  Nóra Meggyesi; Lajos Kalmár; Sándor Fekete; Tamás Masszi; Attila Tordai; Hajnalka Andrikovics
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

2.  The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Christopher A Eide; Anupriya Agarwal; Lauren T Adrian; Huihong You; Amie S Corbin; Fei Yang; Richard D Press; Victor M Rivera; Julie Toplin; Stephane Wong; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

3.  Alternative splicing in oncogenic kinases: from physiological functions to cancer.

Authors:  Sabine Druillennec; Coralie Dorard; Alain Eychène
Journal:  J Nucleic Acids       Date:  2011-10-05

4.  [Discovery of a novel spliceosome of ABL gene (ABL(Δexon7+35INS)) and its association with TKIs resistance in chronic myeloid leukemia].

Authors:  J Pan; Y H Tan; J X Zhao; X H Chen; Z F Xu; J Xu; J M Chang; F Xue; N Zhang; F G Ren; Y F Zhang; X J Wang; H W Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.